Screener
4D Molecular Therapeutics FDMT PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Prepaid expenses and other current assets | 14,472 | 10,479 |
| Total current assets | 405,364 | 413,134 |
| Marketable securities, long-term | 66,739 | 111,379 |
| Property and equipment, net | 13,587 | 14,867 |
| Operating lease right-of-use assets, net | 17,357 | 18,143 |
| Other assets | 9,858 | 9,188 |
| Total assets | $512,905 | $566,711 |
| Liabilities and Stockholders’ Equity |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's PP&E (net)?
- 4D Molecular Therapeutics (FDMT) reported PP&E (net) of $13.59M in Q1 2026.
- How has 4D Molecular Therapeutics's PP&E (net) changed year-over-year?
- 4D Molecular Therapeutics's PP&E (net) decreased by 27.5% year-over-year, from $18.75M to $13.59M.
- What is the long-term trend for 4D Molecular Therapeutics's PP&E (net)?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's PP&E (net) has grown at a 24.0% compound annual growth rate (CAGR), from $5.07M to $14.87M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about 4D Molecular Therapeutics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude